Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Anita D’Souza, Sagar S. Patel et al.|Leukemia|2020Cited by 41
A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)Ravi Vij, Steven M. Devine, Jennifer Le‐Rademacher et al.|Transplantation and Cellular Therapy|2019Cited by 29
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple MyelomaSathish Gopalakrishnan, Parameswaran Hari, Anita D’Souza et al.|Transplantation and Cellular Therapy|2018Cited by 28
Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot StudyArvind Suresh, John M. Hill, Heather A. Wishart et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 4
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current eraBinod Dhakal, Anita D’Souza, Sagar S. Patel et al.|Leukemia|2021Cited by 1